• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Geoffrey I. Shapiro, MD, PhD

Publications

  • Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.Clin Cancer Res. 2013 Jun 1;19(11):3068-77.
    23553849
  • Michaelson MD, Zhu AX, Ryan DP, McDermott DF, Shapiro GI, Tye L, Chen I, Stephenson P, Patyna S, Ruiz-Garcia A, Schwarzberg AB.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Br J Cancer. 2013 Apr 16;108(7):1393-401.
    23511559
  • Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, Paz-Ares L, Cho DC, Infante JR, Alsina M, Gounder MM, Falzone R, Harrop J, White AC, Toudjarska I, Bumcrot D, Meyers RE, Hinkle G, Svrzikapa N, Hutabarat RM, Clausen VA, Cehelsky J, Nochur SV, Gamba-Vitalo C, Vaishnaw AK, Sah DW, Gollob JA, Burris HA.First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.Cancer Discovery. 2013 Apr;3(4):406-17.
    23358650
  • Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S.A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.Clin Cancer Res. 2013 Apr 1;19(7):1873-83.
    23515411
  • Marshall J, Shapiro GI, Uttenreuther-Fischer M, Ould-Kaci M, Stopfer P, Gordon MS.Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.Future Oncol. 2013 Feb;9(2):271-81.
    23414476
  • Haigentz M, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI.Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.Oral Oncol. 2012 Dec;48(12):1281-8.
    22748449
  • Johnson N, Shapiro GI.Cyclin-dependent kinase 4/6 inhibition in cancer therapy.Cell Cycle. 2012 Nov 1;11(21):3913.
    23032266
  • Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Lorusso P.A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.Invest New Drugs. 2012 Oct 6.
    23054208
  • Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P.Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.Cancer Chemother Pharmacol. 2012 Oct 9.
    23053255
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.Clin Cancer Res. 2012 Sep 15;18(18):4973-85.
    22806877
  • Dutta C, Day T, Kopp N, van Bodegom D, Davids MS, Ryan J, Bird L, Kommajosyula N, Weigert O, Yoda A, Fung H, Brown JR, Shapiro GI, Letai A, Weinstock DM.BCL2 suppresses PARP1 function and nonapoptotic cell death.Cancer Res. 2012 Aug 15;72(16):4193-203.
    22689920
  • Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ.Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.J Clin Oncol. 2012 Jul 1;30(19):2348-53.
    22529266
  • Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, Padera R, Engelman JA, Jänne PA, Shapiro GI, Shimamura T, Wong KK.Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.Cancer Res. 2012 Jul 1;72(13):3302-11.
    22552292
  • Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ.A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.Clin Cancer Res. 2012 Jun 15;18(12):3396-406.
    22634319
  • Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res. 2012 Jun 1;18(11):3163-9.
    22496272
  • Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs. 2012 Jun 2.
    22661287
  • Lorusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E.Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.Cancer Chemother Pharmacol. 2011 Apr 3.
    21461891
  • Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko JG, Kharbanda S, Kufe DW.DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.Mol Cancer Ther. 2011 Mar 18.
    21421804
  • Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.J Clin Oncol. 2011 Mar 1;29(7):909-16.
    21282543
  • Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Clin Cancer Res. 2011 Feb 15;17(4):849-60.
    21131552
  • Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.Clin Cancer Res. 2011 Feb 15;17(4):871-9.
    21177764
  • Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.J Thorac Oncol. 2011 Feb;6(2):384-6.
    21252718
  • Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S.Phase I Studies of CBP501,a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors.Clin Cancer Res. 2011 Jan 10.
    21220472
  • Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.Cancer Res. 2010 Dec 15;70(24):10038-43.
    21030459
  • Rodig SJ, Shapiro GI.Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.
    21154129
  • Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene.Cancer Res. 2010 Dec 1;70(23):9827-36.
    20952506
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010 Oct 28;363(18):1727-33.
    20979472
  • Johnson N, Shapiro GI.Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors.Expert Opin Ther Targets. 2010 Nov;14(11):1199-212.
    20932174
  • Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P.A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Early Antitumor Activity of Foretinib.Clin Cancer Res. 2010 Jul 1;16(13):3507-16.
    20472683
  • Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L.Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11501-6.
    20534551
  • Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK.Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.Cancer Cell. 2010 Jun 15;17(6):547-59.
    20541700
  • Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Cancer Chemother Pharmacol. 2010 Jun 3.
    20521052
  • Cleary JM, Shapiro GI.Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.Curr Oncol Rep. 2010 Mar;12(2):87-94. Review.
    20425592
  • Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.J Thorac Oncol. 2009 Sep;4(9):1156-62.
    19704336
  • Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D'Andrea AD, Parvin JD, Shapiro GI.Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.Mol Cell. 2009 Aug 14;35(3):327-39.
    19683496
  • Sos ML,Michel K,Zander T,Weiss J,Frommolt P,Peifer M,Li D,Ullrich R,Koker M,Fischer F,Shimamura T,Rauh D,Mermel C,Fischer S,Stuckrath I,Heynck S,Beroukhim R,Lin W,Winckler W,Shah K,LaFramboise T,Moriarty WF,Hanna M,Tolosi L,Rahnenfuhrer J,Verhaak R,Chiang D,Getz G,Hellmich M,Wolf J,Girard L,Peyton M,Weir BA,Chen TH,Greulich H,Barretina J,Shapiro GI,Garraway LA,Gazdar AF,Minna JD,Meyerson M,Wong KK,Thomas RK.Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.J Clin Invest. 2009 Jun;119(6):1727-40.
    19451690
  • Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,Shapiro GI,Janne PA,Eder JP,Naughton MJ,Ellis MJ,Jones SF,Mekhail T,Zacharchuk C,Vermette J,Abbas R,Quinn S,Powell C,Burris HA.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.Clin Cancer Res. 2009 Apr 1;15(7):2552-8.
    19318484
  • Perera SA,Li D,Shimamura T,Raso MG,Ji H,Chen L,Borgman CL,Zaghlul S,Brandstetter KA,Kubo S,Takahashi M,Chirieac LR,Padera RF,Bronson RT,Shapiro GI,Greulich H,Meyerson M,Guertler U,Chesa PG,Solca F,Wistuba II,Wong KK.HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):474-9.
    19122144
  • Ullrich RT,Zander T,Neumaier B,Koker M,Shimamura T,Waerzeggers Y,Borgman CL,Tawadros S,Li H,Sos ML,Backes H,Shapiro GI,Wolf J,Jacobs AH,Thomas RK,Winkeler A.Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).PLoS ONE. 2008;3(12):e3908.
    19079597
  • Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.Oncogene. 2008 Aug 7;27(34):4702-11.
    18408761
  • Shimamura T,Li D,Ji H,Haringsma HJ,Liniker E,Borgman CL,Lowell AM,Minami Y,McNamara K,Perera SA,Zaghlul S,Thomas RK,Greulich H,Kobayashi S,Chirieac LR,Padera RF,Kubo S,Takahashi M,Tenen DG,Meyerson M,Wong KK,Shapiro GI.Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.Cancer Res. 2008 Jul 15;68(14):5827-38.
    18632637
  • Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12.
    18520291
  • Shimamura T,Shapiro GI.Heat shock protein 90 inhibition in lung cancer.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. Review.
    18520302
  • Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res. 2007 Dec 15;67(24):11867-75.
    18089817
  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jnne PA.PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.Cancer Res. 2007 Dec 15;67(24):11924-32.
    18089823
  • Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M.Allele-Dependent Variation in the Relative Cellular Potency of Distinct EGFR Inhibitors.Cancer Biol Ther. 2007 May;6(5):661-7.
    17495523
  • Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK.LKB1 modulates lung cancer differentiation and metastasis.Nature. 2007 Aug 16;448(7155):807-10.
    17676035
  • Minami Y, Shimamura T, Shah K, Laframboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK.The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.Oncogene. 2007 Jul 26;26(34):5023-7.
    17311002
  • Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jnne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.Cancer Cell. 2007 Jul;12(1):81-93.
    17613438
  • Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.Cancer Res. 2006 Dec 1;66(23):11389-98.
    17145885
  • Cai D, Latham VM, Zhang X, Shapiro GI.Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.Cancer Res. 2006 Sep 15;66(18):9270-80.
    16982772
  • Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI.The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function.Cancer Res. 2006 Aug 1;66(15):7668-77.
    16885368
  • Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.Cancer Res. 2006 Jul 1;66(13):6487-91.
    16818618
  • Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jnne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell. 2006 Jun;9(6):485-95.
    16730237
  • Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22.
    16672372
  • Shapiro GI.Cyclin-dependent kinase pathways as targets for cancer treatment.J Clin Oncol. 2006 Apr 10;24(11):1770-83. Review.
    16603719
  • Cai D, Byth KF, Shapiro GI.AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.Cancer Res. 2006 Jan 1;66(1):435-44.
    16397259
  • Shimamura T, Lowell AM, Engelman JA, Shapiro GI.Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.Cancer Res. 2005 Jul 15;65(14):6401-8.
    16024644
  • Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Clin Cancer Res. 2005 May 1;11(9):3417-24.
    15867243
  • Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M.Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.Oncogene. 2005 Mar 3;24(10):1683-8.
    15674336
  • Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI.A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle.Clin Cancer Res. 2004 Jul 15;10(14):4680-7.
    15269140
  • Shapiro GI.Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s.
    15217973
  • Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS.Novel agents in the treatment of lung cancer: conference summary statement.Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4199s-4204s.
    15217958
  • Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG.Bioluminescent imaging of Cdk2 inhibition in vivo.Nat Med. 2004 Jun;10(6):643-8.
    15122251
  • Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA.The role of metastasis-associated protein 1 in prostate cancer progression.Cancer Res. 2004 Feb 1;64(3):825-9.
    14871807
  • Jiang J, Matranga CB, Cai D, Latham VM, Zhang X, Lowell AM, Martelli F, Shapiro GI.Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.Cancer Res. 2003 Nov 1;63(21):7410-22.
    14612540
  • Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, Quisumbing M, Shapiro G, Witte R, Schiller JH.Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.Lung Cancer. 2003 Oct;42(1):97-102.
    14512193
  • Matranga CB, Shapiro GI.Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.Cancer Res. 2002 Mar 15;62(6):1707-17.
    11912144
  • Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.Clin Cancer Res. 2002 Feb;8(2):620-7.
    11839685
  • Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ.A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):3942-9.
    11751486
  • Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Rollins BJ.A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.Clin Cancer Res. 2001 Jun;7(6):1590-9.
    11410495
  • Shapiro GI, Koestner DA, Matranga CB, Rollins BJ.Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.Clin Cancer Res. 1999 Oct;5(10):2925-38.
    10537362
  • Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ.Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.Oncogene. 1999 Jan 7;18(1):67-77.
    9926921
  • Shapiro GI, Edwards CD, Ewen ME, Rollins BJ.p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.Mol Cell Biol. 1998 Jan;18(1):378-87.
    9418885
  • Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ.Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.Cancer Res. 1995 Dec 15;55(24):6200-9.
    8521414